IP Library Granted Patent US 9,511,023
Granted Patent B2
US 9,511,023 · App. 13/695,593 · Granted Dec 6, 2016

Clay compositions

Inventors: Béatrice Hacher (Angerville La Campagne, FR); Didier Kubiak (Laons, FR); Jeremiah Harnett (Gif-sur-Yvette, FR); Nathalie Mondoly (Le Chesnay, FR)
Assignee: IPSEN PHARMA S.A.S.
A61K9/10A61K35/02G01N17/00A61K9/0095A61K47/26A61K47/32A61K47/38G01N11/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,023
App. No.
13/695,593
Granted
Dec 6, 2016
Kind
B2
Abstract

The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.

Claims (28)

1. A pharmaceutical composition comprising:

(i) 30% to 35% by weight (w/w) natural dioctahedral smectite as the only active ingredient;

(ii) about 0.1% to about 5% by weight (w/w) xanthan gum;

(iii) a pH adjuster;

(iv) 0.01% to 5% by weight (w/w) preservative selected from citric acid, potassium sorbate, ascorbic acid, and mixtures thereof;

(v) 0.5% to 2% by weight (w/w) flavoring agent;

(vi) about 0.02% to 0.5% by weight (w/w) sweetener selected from sodium saccharin, sucralose, a natural sweetener from plant extract, and mixtures thereof; and

(vii) water;

wherein the pH of the composition is between 4 and 6, the composition has a viscosity of between about 1100 mPa·s and about 2500 mPa·s, and the composition is an aqueous suspension or in a semi-solid state.

2. A pharmaceutical composition comprising:

(i) 30% to 40% by weight (w/w) natural dioctahedral smectite as the only active ingredient;

(ii) about 0.1% to about 5% by weight (w/w) xanthan gum;

(iii) a pH adjuster;

(iv) 0.01% to 5% by weight (w/w) preservative selected from citric acid, potassium sorbate, ascorbic acid, and mixtures thereof;

(v) 0.5% to 2% by weight (w/w) flavoring agent;

(vi) about 0.02% to 0.5% by weight (w/w) sweetener selected from sodium saccharin, sucralose, a natural sweetener from plant extract, and mixtures thereof; and

(vii) water;

wherein the pH of the composition is between 4 and 6, the composition has a viscosity of between about 1100 mPa·s and 2500 mPa·s, and the composition is an aqueous suspension or in a semi-solid state.

3. The pharmaceutical composition according to claim 2 , wherein: xanthan gum is present in an amount of from 0.1% to 2% by weight (w/w); the preservative is present in an amount of from 0.1% to 1% by weight (w/w); the pH adjuster is present in an amount that adjusts the composition to a pH of from 4 to 6; the flavoring agent is present in an amount of from 0.5% to 1.5% by weight (w/w); and the sweetner is present in an amount of from 0.03% to 0.3% by weight (w/w).

4. The pharmaceutical composition according to claim 2 , wherein xanthan gum is present in an amount of from about 0.1 to about 2% by weight (w/w).

5. The pharmaceutical composition according to claim 2 , wherein the preservative is present in an amount of from about 0.1 to about 1% by weight (w/w).

6. The pharmaceutical composition according to claim 2 , wherein the sweetener is present in an amount of from about 0.03% to about 0.3% by weight (w/w).

7. The pharmaceutical composition according to claim 2 , wherein the flavoring agent is present in an amount of from 0.5% to 1.5% by weight (w/w) and provides a caramel/cacao flavor.

8. The pharmaceutical composition according to claim 2 , wherein the viscosity is between about 1300 mPa·s and about 2500 mPa·s.

9. The pharmaceutical composition according to claim 2 , which is a ready-to-use formulation.

10. The pharmaceutical composition according to claim 2 , which is a ready-to-use formulation in a sachet.

11. The pharmaceutical composition according to claim 2 , which is a ready-to-use formulation in a tubular sachet.

12. The pharmaceutical composition according to claim 2 , wherein the dioctahedral smectite is sieved.

Assignments (3)
CHANGE OF NAME Recorded Jun 13, 2025
From: IPSEN CONSUMER HEALTHCARE
To: MAYOLY PHARMA FRANCE
Reel/Frame 071575/0859 →
NUNC PRO TUNC ASSIGNMENT Recorded May 27, 2019
From: IPSEN PHARMA SAS
To: IPSEN CONSUMER HEALTHCARE
Reel/Frame 049287/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2012
From: HACHER, BEATRICE; KUBIAK, DIDIER; HARNETT, JEREMIAH; MONDOLY, NATHALIE
To: IPSEN PHARMA S.A.S.
Reel/Frame 029221/0514 →
Priority Claims (1)
EP 10290225 · Apr 29, 2010 · regional
Continuity (1)
Related Publication 20130059016A1 · Mar 7, 2013